ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer
June 01 2020 - 8:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Stacy A. Coen has been appointed Senior Vice
President and Chief Business Officer.
“We are excited to welcome Stacy to the ImmunoGen leadership
team as mirvetuximab soravtansine moves through registration
studies and our early-stage pipeline continues to advance,” said
Mark Enyedy, ImmunoGen’s President and Chief Executive Officer.
“Stacy is a proven business leader with broad corporate strategy
and business development expertise, and will play an important role
in our organization as we continue to execute against our strategy,
explore new opportunities for our pipeline, and seek to bring
mirvetuximab to patients as quickly as possible.”
Ms. Coen brings over 20 years of business and corporate
development experience from leading oncology and rare disease
companies. She joins ImmunoGen from Editas Medicine, where she
served as Vice President, Business Development and was responsible
for business development, strategy, transactions, and alliance
management. Prior to joining Editas, Ms. Coen served in multiple
roles of increasing responsibility at Genzyme Corporation (now
known as Sanofi Genzyme), including Vice President, Head of Rare
Disease Business Development and Licensing, and Vice President,
Global Head of Strategy and Business Development, Multiple
Sclerosis, among others. She currently serves on the Board of
Trustees of Huntington’s Disease Society of America and is a member
of MassBio and the Alliance for Regenerative Medicine (ARM). Ms.
Coen received a BS in Finance and Economics from the University of
Massachusetts and an MBA from the Darden Graduate School of
Business at the University of Virginia.
“I am delighted to join ImmunoGen as the Company works to bring
its first product to market and advance a portfolio of novel ADCs,”
said Ms. Coen. “I look forward to working with the talented team at
ImmunoGen and contributing to the goal of delivering more good days
to people living with cancer.”
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates to improve outcomes for cancer patients. By generating
targeted therapies with enhanced anti-tumor activity and favorable
tolerability profiles, we aim to disrupt the progression of cancer
and offer our patients more good days. We call this our commitment
to “target a better now.”
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD LOOKING STATEMENTS
This press release includes forward-looking statements based on
management's current expectations. These statements include, but
are not limited to, ImmunoGen’s expectations related to the
advancement of ImmunoGen’s research and development programs and
Ms. Coen’s potential contributions to ImmunoGen. For these
statements, ImmunoGen claims the protection of the safe harbor for
forward-looking statements provided by the Private Securities
Litigation Reform Act of 1995. Various factors could cause
ImmunoGen’s actual results to differ materially from those
discussed or implied in the forward-looking statements, and you are
cautioned not to place undue reliance on these forward-looking
statements, which are current only as of the date of this release.
Factors that could cause future results to differ materially from
such expectations include, but are not limited to: the timing and
outcome of ImmunoGen’s pre-clinical and clinical development
processes; the difficulties inherent in the development of novel
pharmaceuticals, including uncertainties as to the timing, expense,
and results of pre-clinical studies, clinical trials, and
regulatory processes; ImmunoGen’s ability to financially support
its product programs; risks and uncertainties associated with the
scale and duration of the COVID-19 pandemic and resulting impact on
ImmunoGen’s industry and business; and other factors more fully
described in ImmunoGen’s Annual Report on Form 10-K for the year
ended December 31, 2019 and other reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200601005090/en/
INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O’Konek
781-895-0600 courtney.okonek@immunogen.com OR FTI Consulting Robert
Stanislaro 212-850-5657 robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024